Session IV - Live Cases from St. Francis Hospital - The Heart Center

Allen Jeremias, MD, MSc, is the Director of Interventional Cardiology Research and Associate Director of the Cardiac Catheterization Laboratory at St. Francis Hospital in Roslyn, New York. He is also a member of the Cardiovascular Research Foundation in New York City where he currently serves as the Director of the Physiology Core Laboratory. He completed his medical training at The Cleveland Clinic Foundation, Stanford University School of Medicine, and Harvard Medical School. He has been a high volume interventional cardiologist since 2006 and recognized as a Top Doctor in the New York Metro Area by Castle Connolly. Dr. Jeremias has significantly contributed to advancing the field of interventional cardiology and he is considered one of the foremost authorities in coronary physiology and intravascular imaging. He is a co-director of the annual St. Francis Intravascular Imaging and Coronary Physiology Workshop, teaching physicians around the world on “Precision Angioplasty”. Dr. Jeremias is presently engaged in a major global study that could change the path of treating clogged arteries. Known as the ILUMIEN IV trial, this major clinical study is evaluating Optical Coherence Tomography (OCT) to guide coronary stent placement. He is also the principal investigator of DEFINE PCI, an international study on assessing the improvement in blood flow after stent placement for severe coronary blockages.

Dr Richard A. Shlofmitz, MD, FACC is the Chairman of Cardiology at St. Francis Hospital, The Heart Center®, in Roslyn, New York. A pioneer in interventional cardiology, Dr. Shlofmitz has worked to advance the field, with a focus on optimizing outcomes with the development of Precision PCI. He is a founding co-director of the annual Intravascular Imaging and Coronary Physiology Workshop. Performing over 1,000 coronary interventions annually, he has one of the largest volumes of experience in PCI. He has the most clinical experience with orbital atherectomy and OCT world-wide. His clinical research interests focus on optimizing coronary interventions and he serves on multiple scientific advisory boards and clinical trial steering committees to further this mission. Dr Shlofmitz has been one of the largest enrollers for multiple clinical trials, including TWILIGHT, ILUMIEN III, and Onyx, with more than 75 publications in peer-reviewed journals and was first to perform coronary intravascular lithotripsy (IVL) in North America as part of the DISRUPT CAD III trial.